Tempus AI reports 30.4% YoY revenue growth in FY2024, driven by genomics and data services. Discover key metrics and ...

The partners plan to build evidence packages that standardize comprehensive genomic profiling and other molecular testing ...

Both TEM and DOCS are technology-intensive healthcare companies leveraging artificial intelligence to enhance their platforms ...

Tempus AI, a health tech firm, offers AI-powered platforms for treatment decisions, patient care, diagnostics, and molecular profiling, with growing revenue and improving margins. The "AI in ...

Tempus signaled its intent to expand beyond cancer when it struck a deal to buy genetic testing company Ambry Genetics for $600 million in November. The company said the takeover would allow it to ...

Artificial intelligence (AI) is rapidly being integrated into every domain of healthcare, giving birth to a new class of tech-driven innovators. Tempus AI TEM and Doximity DOCS stand out as ...

Acquisitions Reinforce Clinical and Data Infrastructure: Tempus AI’s 2025 acquisitions of Deep 6 AI and Ambry Genetics have expanded its clinical footprint to more than 750 sites and 30 million ...

Deep 6’s advanced algorithms complement Tempus AI’s existing platform, strengthening its foothold in AI-driven healthcare. The February 2025 acquisition of Ambry Genetics further expanded its ...

Tempus AI, Inc. (NASDAQ ... including our ability to realize the expected benefits of the acquisition of Ambry Genetics; the potential adverse impact of climate change, natural disasters, health ...

In February 2025, Tempus AI, Inc. (NASDAQ:TEM) completed the acquisition of Ambry Genetics, enhancing its capabilities in genetic testing and data services. Tempus’s stock has experienced ...

Ambry was subsequently acquired by Tempus AI in February 2025 ... From 2016 to 2021, Aaron led Ambry Genetics as CEO and transformed the company into one of the largest hereditary cancer testing ...